Trial · NCT07224776
Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria
NCT07224776, Phase 1, Recruiting, Brigham and Women's Hospital
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria. Trials, record NCT07224776. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07224776
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria
- NCT number
- NCT07224776
- Status
- Recruiting
- Phases
- Phase 1
- Enrollment
- 20 participants, estimated
- Lead sponsor
- Brigham and Women's Hospital
- Conditions
- Proteinuric Renal Disease, Proteinuric Kidney Disease, Proteinuria, Proteinuria in Nephrotic Range
- Interventions
- sparsentan, No sparsentan
- First posted
- 2025-11-05
- Last updated
- 2026-07-30
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in urine to protein creatinine ratio (UPCR) | 8 weeks | The geometric mean percent change in UPCR from screening day to Week 8 |
| Secondary | VSPI discontinuation or interruption | 8 weeks | Incidence of VSPI discontinuation or interruption in the 8 weeks following onset of high-grade proteinuria |
| Secondary | Resolution of Proteinuria | 8 weeks | Incidence of resolution of high-grade proteinuria, defined as recovery of UPCR \< 0.5 g/g in the 8 weeks following onset of high-grade proteinuria |
| Other | Incidence of treatment-related adverse events including any of the following events | 8 weeks | 1. Hyperkalemia defined as serum potassium ≥ 5.5 mmol/L on two separate occasion after ruling out measurement errors and alternative causes and despite appropriate use of diuretics and dietary modification 2. Hypotension defined as decrease in systolic blood pressure ≥20 mm Hg or diastolic blood pressure by ≥10 mm Hg from pre-sparsentan baseline with new dizziness after excluding alternative causes unrelated to sparsentan or determined at the discretion of treating physician 3. AKI defined as serum creatinine persistently ≥ 1.5-fold from pre-sparsentan baseline on 2 consecutive lab checks after excluding alternative causes unrelated to sparsentan or determined at the discretion of treating physician 4. Elevated liver function test defined as newly developed AST or ALT ≥ 3 times of the ULN, with or without an elevation of total serum bilirubin ≥ 2 times ULN after sparsentan initiation |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07224776
GET https://conductscience.org/api/trials/v1/NCT07224776/registered